2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

4:30PM-6:00PM: Abstract Number: 1955

Race Is Associated with Discharge Disposition after Total Knee Arthroplasty (TKA), Which Is Associated with 90-Day Readmission Rate

4M114 ACR/ARHP Abstract: Orthopedics, Low Back Pain & Rehabilitation (1952–1957)

4:30PM-6:00PM: Abstract Number: 1953

Randomized Trial on Exercise at Late-Stage after Total Knee Replacement

4M114 ACR/ARHP Abstract: Orthopedics, Low Back Pain & Rehabilitation (1952–1957)

4:30PM-6:00PM: Abstract Number: 1901

Reduced SPAG17 Expression Links Dysfunctional Cilia, Morphogen Signaling Activation and Multiple Organ Fibrosis: Novel Target for Systemic Sclerosis

4M109 ACR Abstract: Systemic Sclerosis & Rel D/Os–Basic Science (1899–1904)

4:30PM-6:00PM: Abstract Number: 1940

Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety

4M106 ACR Abstract: RA–Treatments III: New Compounds & Biosimilars (1935–1940)

4:30PM-6:00PM: Abstract Number: 1921

Relation of Sensitization and Conditioned Pain Modulation to Post-Knee Replacement Pain

4M103 ACR Abstract: Pain Mechanisms–Basic & Clinical Science (1917–1922)

4:30PM-6:00PM: Abstract Number: 1914

Rheumatic Syndromes Associated with Immune-Checkpoint Inhibitors: A Single-Center Cohort of 61 Patients

4M102 ACR Abstract: Misc Rheum & Inflam DZ I: DADA2, Cardiac Sarcoid,Cancer Immunotherapy(1911–1916)

4:30PM-6:00PM: Abstract Number: 1950

Self-Reported Depression and Anxiety Among US Adults Aged 18-44 Years with Arthritis, National Health Interview Survey 2014-2016

4M117 ARHP Abstract: Pain, Anxiety, & Depression–ARHP I (1946–1951)

4:30PM-6:00PM: Abstract Number: 1897

Single Cell RNA Expression in Lupus Nephritis Comparing African-American and Caucasian Patients Identifies Differential Expression of Interferon Pathway

4M108 ACR Abstract: SLE–Etiology & Pathogenesis I (1893–1898)

4:30PM-6:00PM: Abstract Number: 1939

Sirolimus Treatment in Patients with Refractory Rheumatoid Arthritis: A Double-Arm, Open-Label, phase1/2 Trail

4M106 ACR Abstract: RA–Treatments III: New Compounds & Biosimilars (1935–1940)

4:30PM-6:00PM: Abstract Number: 1951

The Effect and Psychosocial Impact of a Longstanding Telephone Peer Counseling Service on Volunteers with Systemic Lupus Erythematosus

4M117 ARHP Abstract: Pain, Anxiety, & Depression–ARHP I (1946–1951)

4:30PM-6:00PM: Abstract Number: 1911

The Expanding Clinical Spectrum of Patients with Deficiency of Adenosine Deaminase 2 (DADA2)

4M102 ACR Abstract: Misc Rheum & Inflam DZ I: DADA2, Cardiac Sarcoid,Cancer Immunotherapy(1911–1916)

4:30PM-6:00PM: Abstract Number: 1929

The Neutrophil-Lymphocyte Ratio in Newly Diagnosed Rheumatoid Arthritis and Its Ability to Predict Treatment Failure

4M105 ACR Abstract: RA–DX, Manifestations, & Outcomes III: Diagnosis & Prognosis II (1929–1934)

4:30PM-6:00PM: Abstract Number: 1923

Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?

4M104 ACR Abstract: Patient Outcomes, Preferences, & Attitudes I: Beliefs & Behaviors (1923–1928)

4:30PM-6:00PM: Abstract Number: 1912

Treatment of Cardiac Sarcoidosis: A Comparative Study of Steroids Alone Versus Steroids Associated with Immunosuppressive Drugs

4M102 ACR Abstract: Misc Rheum & Inflam DZ I: DADA2, Cardiac Sarcoid,Cancer Immunotherapy(1911–1916)

4:30PM-6:00PM: Abstract Number: 1898

Type I Interferon-Induced Proteins May Facilitate the Occurrence of Long QT Syndrome (LQTS) in Parallel with Anti-Ro/SSA and Anti-Ro52/TRIM21 Antibody Levels in Patients with Systemic Lupus Erythematous (SLE): A Bench to Bedside Approach

4M108 ACR Abstract: SLE–Etiology & Pathogenesis I (1893–1898)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.